Richter's syndrome: Novel and promising therapeutic alternatives
Section snippets
Richter's syndrome
The 2008 World Health Organization (WHO) Classification of Hematopoietic Tumors defines Richter's syndrome as the development of an aggressive lymphoma in patients with a previous or concomitant diagnosis of chronic lymphocytic leukemia (CLL) [1]. The WHO Classification recognizes two distinct pathologic variants of Richter's syndrome: the diffuse large B-cell lymphoma (DLBCL) variant, which is the most frequent, and the rare Hodgkin lymphoma (HL) variant [1]. This review will focus on the
Richter's syndrome diagnosis and course
Richter's syndrome should be suspected in any CLL patient that develops rapid clinical deterioration, fever in the absence of infection, rapid and discordant growth of localized lymph nodes, and sudden and excessive rise in lactate dehydrogenase (LDH) levels. Presence of one or more of these clinical signs and symptoms is only 50–60% specific for Richter's syndrome. In the remaining cases, the histopathologic assessment results in the diagnosis of progressive CLL, prolymphocytic evolution, or
Molecular pathogenesis of Richter's syndrome
Richter's syndrome shows a biased usage of the BCR in the subset 8 configuration, suggesting that it has been selected to bind a restricted set of antigenic epitopes, and supporting a role of BCR signaling in transformation [3]. The particular aggressiveness of BCR subset 8 and its increased propensity of transform into Richter's syndrome may be explained by the strong and unlimited capacity of CLL harboring this BCR configuration to respond to multiple auto-antigens and immune/inflammatory
Chemotherapy approaches for the treatment of Richter's syndrome
Regimens commonly used to treat other B-cell non-Hodgkin lymphomas have been used to treat CLL patients with Richter's syndrome.
Regimens designed for the treatment of highly aggressive lymphomas are severely toxic in Richter's syndrome patients and remission duration is short lasting. The hyper-CVAD regimen, a fractioned cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen, induced a response in 41% (CR 38%) of patients, but the median overall survival (OS) was only 10 months.
Stem cell transplantation in Richter's syndrome
Given the short duration of response with the sole chemotherapy, both autologous and allogeneic stem cell transplantation (SCT) have been explored as post-remission therapy [9], [38]. Unfortunately, most patients (85–90%) with Richter's syndrome are unfit or do not achieve adequate response to the induction to proceed to transplant.
The European Group for Blood and Marrow Transplantation (EBMT) has retrospectively investigated the role of both, autologous and allogeneic SCT, as post-remission
Novel agents
Three aspects are in strong support of the development of novel targeted agents in the field of Richter's syndrome: i) the unsatisfactory response rates that are obtained with conventional chemo-immunotherapy, and the short response duration if not consolidated with SCT; ii) the low number of cases that can proceed to transplant because of the constraints imposed by a combination of age, poor performance status, lack donor availability and refractoriness to induction treatments; and iii) the
Summary
Suggested management of Richter's syndrome includes (Fig. 1): i) in the presence of a clinical suspicion of Richter's syndrome transformation, perform a 18FDG PET/CT and tailor the open biopsy of the index lesion according to its results; ii) if the biopsy reveals an aggressive lymphoma, establish its clonal relationship with CLL by IGHV-D-J rearrangement analysis; iii) if the CLL and Richter's syndrome are clonally unrelated, treat the disease as a de novo DLBCL; iv) if the CLL and Richter's
Conflict of interest
The author has no conflict of interest.
References (45)
- et al.
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
Blood
(2011) - et al.
Origin of the Hodgkin/Reed-Sternberg cells in chronic lymphocytic leukemia with “Hodgkin's transformation”
Blood
(1998) - et al.
Clonal relation in a case of CLL, ALCL, and Hodgkin composite lymphoma
Blood
(2002) - et al.
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia
Blood
(2012) - et al.
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
Lancet
(2007) - et al.
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
Lancet Oncol
(2014) - et al.
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
Lancet Oncol
(2015) - et al.
Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib
Blood
(2015) - et al.
EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma
Blood
(2008) - et al.
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial
Blood
(2012)
Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8
Blood
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
Blood
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome
Clin Lymphoma Myeloma Leuk
The efficacy of ibrutinib in the treatment of Richter syndrome
Blood
Chronic lymphocytic leukemia/small lymphocytic lymphoma
IgVH mutational status and clonality analysis of Richter’s transformation
Am J Surg Pathol
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome
Clin Cancer Res
Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior
Haematologica
Distinct clonal origin in two cases of Hodgkin's lymphoma variant of Richter's syndrome associated with EBV infection
Am J Surg Pathol
Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients
Br J Haematol
Hodgkin transformation of chronic lymphocytic leukemia: incidence, outcomes, and comparison to de novo Hodgkin lymphoma
Am J Hematol
Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome
Br J Haematol
Cited by (21)
2-[<sup>18</sup>F]-FDG PET/CT Role in Detecting Richter Transformation of Chronic Lymphocytic Leukemia and Predicting Overall Survival
2021, Clinical Lymphoma, Myeloma and LeukemiaCitation Excerpt :This evidence is related to the fact that tumor size is not a prognostic factor for the risk of RS, and it is intrinsically included in MTV and TLG. The detection of patients that will develop RS is crucial because RS significantly affects survival, and common biological and clinical features have some limitations in this field.6 The potential utility of PET/CT may help to better stratify the risk of transformation and enabling personalized therapy.
Richter Syndrome With Extensive Isolated Pleural Extranodal Involvement: The Importance of PET/CT Imaging
2017, Archivos de BronconeumologiaCytogenomic features of Richter transformation
2023, Molecular CytogeneticsRichter's Syndrome of the Central Nervous System
2021, Canadian Journal of Neurological SciencesA case of T-cell chronic lymphocytic leukemia progressing to Richter syndrome with central nervous system involvement in a dog
2020, Veterinary Clinical Pathology